179 related articles for article (PubMed ID: 22582991)
1. Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
Aridoss G; Zhou B; Hermanson DL; Bleeker NP; Xing C
J Med Chem; 2012 Jun; 55(11):5566-81. PubMed ID: 22582991
[TBL] [Abstract][Full Text] [Related]
2. Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017): a novel scaffold that resensitizes multidrug resistant leukemia cells to chemotherapy.
Das SG; Hermanson DL; Bleeker N; Lowman X; Li Y; Kelekar A; Xing C
ACS Chem Biol; 2013 Feb; 8(2):327-35. PubMed ID: 23102022
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.
Das SG; Srinivasan B; Hermanson DL; Bleeker NP; Doshi JM; Tang R; Beck WT; Xing C
J Med Chem; 2011 Aug; 54(16):5937-48. PubMed ID: 21780800
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
Das SG; Doshi JM; Tian D; Addo SN; Srinivasan B; Hermanson DL; Xing C
J Med Chem; 2009 Oct; 52(19):5937-49. PubMed ID: 19743858
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
Doshi JM; Tian D; Xing C
J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
[TBL] [Abstract][Full Text] [Related]
6. CXL146, a Novel 4
Bian T; Tagmount A; Vulpe C; Vijendra KC; Xing C
Mol Pharmacol; 2020 Jun; 97(6):402-408. PubMed ID: 32276963
[TBL] [Abstract][Full Text] [Related]
7. 4H-Chromene-based anticancer agents towards multi-drug resistant HL60/MX2 human leukemia: SAR at the 4th and 6th positions.
Puppala M; Zhao X; Casemore D; Zhou B; Aridoss G; Narayanapillai S; Xing C
Bioorg Med Chem; 2016 Mar; 24(6):1292-7. PubMed ID: 26867486
[TBL] [Abstract][Full Text] [Related]
8. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
9. A novel SERCA inhibitor demonstrates synergy with classic SERCA inhibitors and targets multidrug-resistant AML.
Bleeker NP; Cornea RL; Thomas DD; Xing C
Mol Pharm; 2013 Nov; 10(11):4358-66. PubMed ID: 24079514
[TBL] [Abstract][Full Text] [Related]
10. SERCA and P-glycoprotein inhibition and ATP depletion are necessary for celastrol-induced autophagic cell death and collateral sensitivity in multidrug-resistant tumor cells.
Xu SW; Law BYK; Qu SLQ; Hamdoun S; Chen J; Zhang W; Guo JR; Wu AG; Mok SWF; Zhang DW; Xia C; Sugimoto Y; Efferth T; Liu L; Wong VKW
Pharmacol Res; 2020 Mar; 153():104660. PubMed ID: 31982489
[TBL] [Abstract][Full Text] [Related]
11. Exploring the Structure-Activity Relationship and Mechanism of a Chromene Scaffold (CXL Series) for Its Selective Antiproliferative Activity toward Multidrug-Resistant Cancer Cells.
Bian T; Chandagirikoppal Vijendra K; Wang Y; Meacham A; Hati S; Cogle CR; Sun H; Xing C
J Med Chem; 2018 Aug; 61(15):6892-6903. PubMed ID: 29995404
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic and multidrug resistance reversal activities of novel 1,4-dihydropyridines against human cancer cells.
Shekari F; Sadeghpour H; Javidnia K; Saso L; Nazari F; Firuzi O; Miri R
Eur J Pharmacol; 2015 Jan; 746():233-44. PubMed ID: 25445037
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents.
Ojima I; Borella CP; Wu X; Bounaud PY; Oderda CF; Sturm M; Miller ML; Chakravarty S; Chen J; Huang Q; Pera P; Brooks TA; Baer MR; Bernacki RJ
J Med Chem; 2005 Mar; 48(6):2218-28. PubMed ID: 15771464
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
[TBL] [Abstract][Full Text] [Related]
16. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
17. Antitumor agents 286. Design, synthesis, and structure-activity relationships of 3'R,4'R-disubstituted-2',2'-dimethyldihydropyrano[2,3-f]chromone (DSP) analogues as potent chemosensitizers to overcome multidrug resistance.
Zhou T; Shi Q; Bastow KF; Lee KH
J Med Chem; 2010 Dec; 53(24):8700-8. PubMed ID: 21082774
[TBL] [Abstract][Full Text] [Related]
18. 1-[4-(2-Aminoethoxy)phenylcarbonyl]-3,5-bis-(benzylidene)-4-oxopiperidines: a novel series of highly potent revertants of P-glycoprotein associated multidrug resistance.
Das U; Molnár J; Baráth Z; Bata Z; Dimmock JR
Bioorg Med Chem Lett; 2008 Jun; 18(12):3484-7. PubMed ID: 18513966
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Anticancer Cytotoxicity of Azaaurones Overcoming Multidrug Resistance.
Tóth S; Szepesi Á; Tran-Nguyen VK; Sarkadi B; Német K; Falson P; Di Pietro A; Szakács G; Boumendjel A
Molecules; 2020 Feb; 25(3):. PubMed ID: 32050702
[TBL] [Abstract][Full Text] [Related]
20. Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR).
Lee CH
Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):43-52. PubMed ID: 14754411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
